Advanced Medical Optics Names New Chief Financial Officer, Announces Management Changes.
Mr. Lambert is a seasoned executive who brings to AMO approximately 20 years of experience and a diverse financial background. Most recently, he was senior vice president and chief financial officer of Quest Software, Inc. where he drove productivity gains and controlled costs, improved cash flow performance, integrated multiple acquisitions, and improved resource allocation processes.
Prior to joining Quest in November 2004, Mr. Lambert was chief financial officer at Quantum Corporation, and Nervewire, Inc., a pre-IPO internet services firm. He was also chief financial officer for a division of Lucent Technologies. Mr. Lambert holds a master's degree from Harvard Graduate School of Business Administration and a bachelor's degree from Stonehill College.
"Michael is an outstanding addition to our executive leadership team," said Jim Mazzo, AMO chairman, president and chief executive officer. "He is an experienced leader with an excellent reputation and a deep understanding of the financial requirements of a public company with a global presence. I expect Michael to play an integral role in advancing our strategy to achieve sustained, profitable growth through innovative vision technologies that enhance the quality of life for people of all ages. I am pleased to welcome Michael to AMO."
At AMO, Mr. Lambert will oversee the company's finance, accounting, tax, treasury and information technology functions and report directly to Mr. Mazzo.
Before Mr. Lambert's appointment, Richard (Randy) A. Meier, 48, held positions of chief financial officer and chief operating officer at AMO. Mr. Meier will continue as AMO's chief operating officer and assume additional responsibility for management of the company's cataract/implant business and global customer services function, while maintaining his existing management responsibilities for AMO's eye care business and the company's global manufacturing and supply chain operations. C. Russell Trenary, III, 50, who was previously president of the company's cataract/implant business, has been named executive vice president of global public policy and medical education encompassing all of AMO's businesses and product lines. Both executives will continue to report directly to Mr. Mazzo.
About Advanced Medical Optics (AMO)
AMO is focused on providing the full range of advanced refractive technologies and support to help eye care professionals deliver optimal vision and lifestyle experiences to patients of all ages. Products in the cataract/implant line include intraocular lenses (IOLs), phacoemulsification systems, viscoelastics, and related products used in ocular surgery. AMO owns or has the rights to such product brands as ReZoom([R]), Tecnis([R]), Clariflex([R]), Sensar([R]), and Verisyse([R]) IOLs, Sovereign([R]), Sovereign([R]) Compact and WhiteStar Signature([TM]) phacoemulsification systems with WhiteStar([R]) technology, Healon([R]) viscoelastics, and the Baerveldt([R]) glaucoma shunt. Products in the laser vision correction line include wavefront diagnostic devices, femtosecond lasers and associated patient interface devices, and excimer laser vision correction systems and treatment cards. AMO brands in the laser vision correction business include Star S4 IR([R]), WaveScan Wavefront([R]), Advanced CustomVue([TM]), IntraLase([R]) and IntraLasik([R]). Products in the contact lens care line include disinfecting solutions, enzymatic cleaners and lens rewetting drops. Among the eye care product brands the company possesses are COMPLETE([R]), COMPLETE([R]) Blink-N-Clean([R]), Consept([R])F, Consept([R]) 1 Step, Oxysept([R]) 1 Step, UltraCare([R]), Ultrazyme([R]), Total Care([TM]) and blink[TM] branded products. AMO is based in Santa Ana, California, and employs approximately 4,200 worldwide. The company has operations in 24 countries and markets products in approximately 60 countries. For more information, visit the company's Website at www.amo-inc.com.
All forward-looking statements in this press release, such as Mr. Mazzo's statements, are based on estimates and assumptions and represent AMO's judgment only as of the date of this press release. Actual results may differ from current expectations based on a number of factors. Therefore, the reader is cautioned not to rely on these forward-looking statements. AMO disclaims any intent or obligation to update these forward-looking statements. Additional information concerning these and other risk factors may be found in previous press releases issued by AMO and AMO's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in AMO's 2006 Form 10-K filed in March 2007 and Form 10-Q filed in August 2007. Copies of press releases and additional information about AMO are available at www.amo-inc.com.
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 9, 2007|
|Previous Article:||Grandview Gold Inc. Rated 'Speculative Buy,' Target Price 3.54 by Beacon Equity Research.|
|Next Article:||F5 Launches Web-Based Solution Selling Training Program to Drive Channel Partners' Success.|